3,4,5,6-Tetrahydro-2,6-methano-4 beta-amino-1-benzoxocin derivatives, process for their preparation and compositions containing them
申请人:GLAXO GROUP LIMITED
公开号:EP0024843A1
公开(公告)日:1981-03-11
Compounds are disclosed of general formula
wherein
R1 represents a hydrogen atom or C1-4 alkyl or C2-4 alkenyl group, or the group COANH2, CSANH2, or COANHCOCH2NH2 in which A is methylene optionally substituted by a C1-3 alkyl group; and R2 represents a hydrogen atom or a C1-4 alkyl group; or NR1R2 forms a piperidino, piperazino or N-methylpiperazino group;
R3 represents a C1-4 alkyl group or a benzyl group;
R4 represents a hydrogen or halogen atom; and
R5 represents a hydrogen atom or a C1-4 alkyl or C1-4 alkoxy group, with the proviso that one of R4 and Rs is a hydrogen atom and physiologically acceptable salts and bioprecursors thereof.
The compounds exert efforts on the central nervous system and, in particular exhibit anxiolytic and anti-convulsant activity. The compounds may be formulated with pharmaceutically acceptable carriers or diluents for administration in conventional manner.
Benzoxocin derivatives having anxiolytic and anti-convulsant activities
申请人:Glaxo Group Limited
公开号:US04315006A1
公开(公告)日:1982-02-09
Compounds are disclosed of general formula ##STR1## wherein R.sub.1 represents a hydrogen atom or C.sub.1-4 alkyl or C.sub.2-4 alkenyl group, or the group COANH.sub.2, CSANH.sub.2, or COANHCOCH.sub.2 NH.sub.2 in which A is methylene optionally substituted by a C.sub.1-3 alkyl group; and R.sub.2 represents a hydrogen atom or a C.sub.1-4 alkyl group; or NR.sub.1 R.sub.2 forms a piperidino, piperazino or N-methylpiperazino group; R.sub.3 represents a C.sub.1-4 alkyl group or a benzyl group; R.sub.4 represents a hydrogen or halogen atom; and R.sub.5 represents a hydrogen atom or a C.sub.1-4 alkyl or C.sub.1-4 alkoxy group, with the proviso that one of R.sub.4 and R.sub.5 is a hydrogen atom and physiologically acceptable salts and bioprecursors thereof. The compounds exert effects on the central nervous system and, in particular exhibit anxiolytic and anti-convulsant activity. The compounds may be formulated with pharmaceutically acceptable carriers or diluents for administration in conventional manner.